PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies

被引：0

作者：

Diab, A. ^{[1
]}

Hurwitz, M. E. ^{[2
]}

Tannir, N. ^{[3
]}

Bernatchez, C. ^{[1
]}

Haymaker, C. ^{[1
]}

Bentebibel, S. E. ^{[1
]}

Curti, B. D. ^{[4
,5
]}

Wong, M. K. K. ^{[1
]}

Gergel, I. ^{[6
]}

Tagliaferri, M. ^{[7
]}

Zalevsky, J. ^{[8
]}

Hoch, U. ^{[9
]}

Aung, S. ^{[7
]}

Imperiale, M. ^{[7
]}

Cho, D. ^{[10
]}

Tykodi, S. S. ^{[11
,12
]}

Puzanov, I. ^{[13
]}

Kluger, H. ^{[14
]}

Hwu, P. ^{[1
]}

Sznol, M. ^{[15
]}

机构：

[1] MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX USA

[2] Yale Sch Med, Div Med Oncol, Dept Internal Med, New Haven, CT USA

[3] MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX USA

[4] Providence Canc Ctr, Dept Genitourinary Oncol Res, Portland, OR USA

[5] Earle A Chiles Res Inst, Portland, OR USA

[6] Nektar Therapeut, Dept Drug Dev, San Francisco, CA USA

[7] Nektar Therapeut, Dept Clin Dev, San Francisco, CA USA

[8] Nektar Therapeut, Dept Biol & Preclin Dev, San Francisco, CA USA

[9] Nektar Therapeut, Dept Clin Pharmacol, San Francisco, CA USA

[10] Dept Med Oncol, NYU Med Oncol Associates, New York, NY USA

[11] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA

[12] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[13] Roswell Pk Canc Inst, Dept Med Oncol, Buffalo, NY 14263 USA

[14] Yale Breast Ctr, Dept Med Oncol, New Haven, CT USA

[15] Yale Univ, Dept Med Oncol, Sch Med Med Oncol, New Haven, CT USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1212TiP

引用

页数：2

共 50 条

[41] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations.
Heymach, John
Opdam, Frans
Barve, Minal A.
Gibson, Neil
Sadrolhefazi, Behbood
Serra, Josep
Yamamoto, Noboru
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
Kudo, Toshihiro
Murai, Yoshiyuki
Kojima, Yoshitsugu
Uehara, Kenji
Satoh, Taroh
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 354 - 362
[43] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations.
Heymach, John
Opdam, Frans
Barve, Minal
Gibson, Neil
Sadrolhefazi, Behbood
Serra, Josep
Yamamoto, Noboru
CANCER RESEARCH, 2022, 82 (12)
[44] A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.
Fathi, Amir Tahmasb
Donnellan, William Bruce
Lyons, Roger M.
Maris, Michael B.
Kim, Tae Min
Kim, Won Seog
Schiller, Gary J.
Abboud, Camille N.
Arellano, Martha Lucia
Cull, Elizabeth H.
Yee, Karen W. L.
Townsley, Danielle Michelle
Wang, Fujun
Bothos, John G.
Yao, Nai-Shun
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[45] Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Hamadani, Mehdi
Collins, Graham P.
Caimi, Paolo F.
Samaniego, Felipe
Spira, Alexander
Davies, Andrew
Radford, John
Menne, Tobias
Karnad, Anand
Zain, Jasmine M.
Fields, Paul
Havenith, Karin
Cruz, Hans G.
He, Shui
Boni, Joseph
Feingold, Jay
Wuerthner, Jens
Horwitz, Steven
LANCET HAEMATOLOGY, 2021, 8 (06): : E433 - E445
[46] A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma
Shah, Nina D.
Turtle, Cameron J.
Cowan, Andrew J.
Chavez, Julio C.
Budde, Lihua E.
Marcondes, Mario Q.
Lee, Zachary
Lin, Wei
Zalevsky, Jonathan
Tagliaferri, Mary
Patel, Krina K.
BLOOD, 2019, 134
[47] A phase I open-label dose-escalation study of AL2846 in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
Liu, Rui
Deng, Ting
Bai, Ming
Zhang, Le
Ning, Tao
Wang, Xia
Ji, Zhi
Yang, Yuchong
Ge, Shaohua
Li, Hongli
Duan, Jingjing
Ba, Yi
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
Alistar, Angela Tatiana
El-Khoueiry, Anthony B.
Mahalingam, Devalingam
Mita, Monica M.
Kang, Hwankyu
Yang, Yeong-In
Ahn, Jiye
Kim, Jeongjun
Choi, Baejung
Jeon, Yeejin
Jung, Chunwon
Jeon, Borami
Kim, Jaeseung
Nam, Kiyean
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[49] IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma: An open-label, multicenter, phase 1b/2 dose escalation and expansion study (IMM01-04)
Song, Zhengbo
Tong, Xu
Zhang, Yan
Zhu, Hui
Zhao, Yanqiu
Yu, Xiaoqing
Ai, Xinghao
Zong, Zhenzhen
Zhao, Xiwen
Gao, Siman
Lu, Qiying
Tian, Wenzhi
Lu, Shun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Schenker, Michael
Burotto, Mauricio
Richardet, Martin
Ciuleanu, Tudor-Eliade
Goncalves, Anthony
Steeghs, Neeltje
Schoffski, Patrick
Ascierto, Paolo A.
Maio, Michele
Lugowska, Iwona
Lupinacci, Lorena
Leary, Alexandra
Delord, Jean-Pierre
Grasselli, Julieta
Tan, David S. P.
Friedmann, Jennifer
Vuky, Jacqueline
Tschaika, Marina
Konduru, Somasekhar
Vemula, Sai Vikram
Slepetis, Ruta
Kollia, Georgia
Pacius, Misena
Duong, Quyen
Huang, Ning
Doshi, Parul
Baden, Jonathan
Di Nicola, Massimo
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08) : 1 - 11

← 1 2 3 4 5 →